Elicio Therapeutics Announces Prelim. Disease-Free Survival Analysis From Phase 1a Study Of ELI-002 7P Showing Patients Receiving ELI-002 7P At Dose Of 4.9mg AMP-Peptide Were Yet To Reach Midian DFS Endpoint As Of May 24 Cutoff Date

6/27/24 4:02:35 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELTX alert in real time by email

Get the next $ELTX alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ELTX

Date	Price Target	Rating	Analyst

More analyst ratings

$ELTX
Press Releases

Fastest customizable press release news feed in the world

View All

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients

At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS ("mKRAS") induced by ELI-00277% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacyELI-002 induced both CD4+ and CD8+ mKRAS-specific T cell responses in most patients, and evidence of antigen-spreading to patient-specific neoantigens not included in ELI-002 was observed Final event-driven disease-free survival ("DFS") analysis for the randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P mo

8/12/25 8:00:00 AM ET

$ELTX

Biotechnology: Pharmaceutical Preparations

Health Care

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival ("DFS") expected in Q4 2025 Secured $10 million financing in Q2 2025; Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 final analysis BOSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for t

8/7/25 4:30:00 PM ET

$ELTX

Biotechnology: Pharmaceutical Preparations

Health Care

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

The AMPLIFY-7P study of ELI-002 7P successfully passes event-driven interim analysis for efficacy, futility, and safety by the IDMC The Company views the IDMC's positive recommendation as an indication that ELI-002 7P has shown preliminary signals of efficacy Final disease-free survival analysis is anticipated to occur in Q4 2025Elicio previously reached alignment with the FDA on key elements of the planned pivotal Phase 3 study designThe Company's current cash runway extends into Q1 2026, past the anticipated final DFS analysis BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a

8/5/25 7:00:00 AM ET

$ELTX

Biotechnology: Pharmaceutical Preparations

Health Care

Elicio Therapeutics Announces Prelim. Disease-Free Survival Analysis From Phase 1a Study Of ELI-002 7P Showing Patients Receiving ELI-002 7P At Dose Of 4.9mg AMP-Peptide Were Yet To Reach Midian DFS Endpoint As Of May 24 Cutoff Date

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ELTX

Elicio Therapeutics Announces Prelim. Disease-Free Survival Analysis From Phase 1a Study Of ELI-002 7P Showing Patients Receiving ELI-002 7P At Dose Of 4.9mg AMP-Peptide Were Yet To Reach Midian DFS Endpoint As Of May 24 Cutoff Date

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ELTX

$ELTX
Insider Trading

SEC Form 4 filed by Director Chudnovsky Yekaterina

SEC Form 4 filed by Director Ashe Carol Gail

SEC Form 4 filed by Director Nissenson Allen

$ELTX
SEC Filings

Elicio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Elicio Therapeutics Inc.

Elicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ELTX
Press Releases

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

$ELTX
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

SEC Form SC 13D/A filed by Elicio Therapeutics Inc. (Amendment)

$ELTX
Leadership Updates

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

Elicio Therapeutics Announces Prelim. Disease-Free Survival Analysis From Phase 1a Study Of ELI-002 7P Showing Patients Receiving ELI-002 7P At Dose Of 4.9mg AMP-Peptide Were Yet To Reach Midian DFS Endpoint As Of May 24 Cutoff Date

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ELTX

Elicio Therapeutics Announces Prelim. Disease-Free Survival Analysis From Phase 1a Study Of ELI-002 7P Showing Patients Receiving ELI-002 7P At Dose Of 4.9mg AMP-Peptide Were Yet To Reach Midian DFS Endpoint As Of May 24 Cutoff Date

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $ELTX

$ELTX Insider Trading

SEC Form 4 filed by Director Chudnovsky Yekaterina

SEC Form 4 filed by Director Ashe Carol Gail

SEC Form 4 filed by Director Nissenson Allen

$ELTX SEC Filings

Elicio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Elicio Therapeutics Inc.

Elicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ELTX Press Releases

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

$ELTX Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

SEC Form SC 13D/A filed by Elicio Therapeutics Inc. (Amendment)

$ELTX Leadership Updates

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

Recent Analyst Ratings for
$ELTX

Recent Analyst Ratings for
$ELTX

$ELTX
Insider Trading

$ELTX
SEC Filings

$ELTX
Press Releases

$ELTX
Large Ownership Changes

$ELTX
Leadership Updates